International Stem Cell Corporation (OTCBB: ISCO) (www.internationalstemcell.com)
today announced it has appointed MZ Group as its investor relations
advisor. MZ will assist International Stem Cell with investor relations
consulting, corporate communications and investor and shareholder
outreach. ISCO also announced the promotion of Dr. Simon Craw to the
position of Executive Vice President with responsibility for Business
Development and Investor Relations.
"MZ is an excellent investor relations partner for several reasons,"
said Dr. Andrey Semechkin, Ph.D., Chief Executive Officer of
International Stem Cell. "With our recent financing and steady progress
in our Lifeline Skin Care and Cell Technology businesses, we have a
tremendous opportunity to introduce our company to a wide variety of
investors. MZ has access to a large pool of potential investors who may
be interested in an emerging life sciences company such as ours.
"We also look forward to steadily expanding our corporate communications
efforts with the media and the life sciences industry to further
solidify our corporate brands. With this in mind I have promoted Dr.
Craw to a new position of EVP, to be responsible for Business
Development and oversee our Investor Relations program in addition to
his existing responsibly for our Stem Cell banking program. As part of
his new role Dr. Craw will work closely with our VP of Research and
Development and maintain his involvement in the development of our
technologies."
"We see a terrific opportunity to help management achieve their goals
and objectives," said Ted Haberfield, Managing Partner of MZ Group North
America. "With advanced R&D and manufacturing facilities located in
California and Maryland and its patented parthenogenetic stem cell
technology to treat human degenerative diseases, the Company is in the
advanced stages of developing multiple groundbreaking commercial
applications. We believe investors will be extremely excited to learn
more about International Stem Cell Corporation."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes
(eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of differing
genders, ages and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true stem
cell bank, UniStemCell™. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology, and cell-based skin care products
through its subsidiary Lifeline Skin Care. More information is available
at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
International Stem Cell Corporation
Dr. Simon Craw, Executive Vice
President
Phone: 760-940-6383
Email: ir@intlstemcell.com
or
Investor
Relations:
MZ Group
Mark McPartland
Senior Vice President
Phone:
212-301-7130
Email: markmcp@mzgroup.us
Web:
www.mz-ir.com